China NMPA approves Astellas Pharma's Padcev in combination with Keytruda to treat advanced bladder cancer
Astellas Pharma Inc. announced that China’s National Medical Products Administration (NMPA) has approved Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer (la…